DNANYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Ginkgo Bioworks Holdings, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$10.07−0.20 (-1.95%)
Close on Oct 19, 2026
- Market cap
- $625.29M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2018 to 2025
Operating margin
-185.3%−6.5 pts over 5 years
Net margin
-183.8%−18.6 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -25.1% | -29.1% | +17.3% | – |
Returns and balance sheet
8 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2018 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | – | -51.1% | |
| Return on assets | – | – | -25.0% | |
| Current ratio | – | 5.83 | 4.92 | |
| Interest coverage | – | -57.5× | – | |
| Capex to revenue | – | 75.4% | 4.5% | |
| Diluted shares | – | 32M | 55M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Ginkgo Bioworks generated $1.29B from operations and spent $244.80M on capital expenditure, dividends and share buybacks. 90% of that went back into the business.
Generated
$1.29B
Used
$244.80M
Capital expenditure$219.80M90%Dividends$00%Share buybacks$25.00M10%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-183.8%
×Asset turnover0.14×
×Equity multiplier2.04×
=Return on equity, FY2025-51.1%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -183.8% | 0.14× | 2.04× | -51.1% |
| FY2024 | -240.9% | 0.15× | 1.68× | -60.3% |
| FY2023 | -355.1% | 0.12× | 1.48× | -63.0% |
| FY2022 | -440.6% | 0.21× | 1.42× | -129.9% |
| FY2021 | -583.1% | 0.23× | 1.40× | -186.1% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$312.76M
- Cash generatingOperating cash flow above zero-$171.06M
- Return on assets improvedROA up on the prior year-32.8% → -22.7%
- Earnings backed by cashOperating cash flow above net income-$171.06M vs -$312.76M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose5.62 → 4.92
- No dilutionShare count did not rise52M → 55M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.14 → 0.12